Approval for the addition of the cpsa assay to the bayer advia ims system. The device, as modified, will be marketed under the trade name bayer advia ims cpsa assay and is indicated as an aid in the detection of prostate cancer in men aged 50 years or older in conjunction with digital rectal exam.
Device | BAYER ADVIA IMS CPSA ASSAY |
Classification Name | Antigen(complexed),prostate Specific,(cpsa) |
Generic Name | Antigen(complexed),prostate Specific,(cpsa) |
Applicant | SIEMENS HEALTHCARE DIAGNOSTICS |
Date Received | 2003-07-16 |
Decision Date | 2003-09-02 |
PMA | P990055 |
Supplement | S007 |
Product Code | NAF |
Advisory Committee | Immunology |
Supplement Type | Real-time Process |
Supplement Reason | Labeling Change - Indications/instructions/shelf Life/tradename |
Expedited Review | No |
Combination Product | No |
Applicant Address | SIEMENS HEALTHCARE DIAGNOSTICS 333 Coney Street walpole, MA 02032-1516 |
Supplemental Filings
Supplement Number | Date | Supplement Type |
P990055 | | Original Filing |
S024 |
2022-03-22 |
30-day Notice |
S023 |
2021-04-01 |
30-day Notice |
S022 |
2020-07-31 |
30-day Notice |
S021 |
2020-03-09 |
30-day Notice |
S020 |
2020-02-21 |
30-day Notice |
S019 | | |
S018 |
2019-02-01 |
30-day Notice |
S017 |
2018-07-27 |
Real-time Process |
S016 |
2017-09-29 |
Normal 180 Day Track |
S015 |
2015-05-07 |
Normal 180 Day Track |
S014 |
2012-03-26 |
Normal 180 Day Track No User Fee |
S013 |
2010-08-06 |
30-day Notice |
S012 |
2009-04-10 |
Normal 180 Day Track No User Fee |
S011 |
2009-02-06 |
30-day Notice |
S010 |
2009-03-06 |
Real-time Process |
S009 |
2006-05-17 |
Normal 180 Day Track No User Fee |
S008 |
2005-07-22 |
Real-time Process |
S007 |
2003-07-16 |
Real-time Process |
S006 |
2003-04-21 |
Real-time Process |
S005 |
2002-03-28 |
Normal 180 Day Track |
S004 |
2002-03-06 |
Normal 180 Day Track |
S003 |
2001-09-20 |
Normal 180 Day Track |
S002 |
2001-09-20 |
Normal 180 Day Track |
S001 |
2001-03-27 |
Normal 180 Day Track |
NIH GUDID Devices